Supporting information for

Synthesis and properties of DNA oligomers containing stereopure phosphorothioate linkages and C-5 modified deoxyuridine derivatives

Rintaro Iwata Hara,^{*a,b*} Reijiro Yoshino,^{*a*} Yohei Nukaga, ^{*a*} Yusuke Maeda, ^{*a*} Kazuki Sato ^{*a*} and Takeshi Wada ^{*a*,*}

(a) Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.

- (b) Department of Neurology and Neurological Science, Tokyo Medical and Dental University, 1-5-
- 45, Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.

* E-mail: twada@rs.tus.ac.jp

Table of contents

Synthesis of compounds	3-8
NMR spectra of compounds	9-25
HPLC profiles of synthesized DNA oligomers	26-30
3D view of DNA/DNA duplex	31
HPLC analysis for evaluation of RNase H activity	32



Figure S1. The synthetic scheme of compound 1e

Compound 1e

5'-O-(4,4'-Dimethoxytrityl)-5-iodo-2'-deoxyuridine (1d) (0.658 g, 1.0 mmol) was dissolved in dry DMF (2.2 mL). Triethylamine (TEA) (2.8 mL, 20 mmol), CuI (38 mg, 0.2 mmol), tetrakis(triphenylphosphine)palladium (0.117 g, 0.1 mmol) and a 1 M solution of propyne in DMF (10 mL) were successively added to the solution, which was stirred for 7 h at room temperature. The mixture was diluted with toluene–ethyl acetate (30 mL, 1:1, v/v) and washed with a saturated aqueous solution of ammonium chloride (20 mL × 2) and an aqueous solution of sodium chloride (20 mL). The water layers were then combined and extracted with toluene–ethyl acetate (20 mL, 1:1, v/v). The combined organic layers were dried over Mg₂SO₄, filtered, and concentrated. The crude product was purified by silica gel column chromatography [neutral silica, hexane–ethyl acetate (13:7–15:5, v/v), 0.5% pyridine] to afford **1e** as slightly yellow foam (0.462 g, 0.81 mmol, 81%).

¹H NMR (400 MHz, CHCl₃): δ 8.89 (br, 1H), 7.98 (s, 1H), 7.45–7.42 (m, 2H), 7.37–7.19 (m, 7H), 6.85 (dd, J = 8.9, 0.9 Hz, 4H), 6.31 (dd, J = 7.6, 5.9 Hz, 1H), 4.57–4.53 (m, 1H), 4.09 (q, J = 3.0 Hz, 1H), 3.79 (s, 6H), 3.37 (d, J = 3.2 Hz, 2H), 2.59 (d, J = 3.7 Hz, 1H), 2.49 (ddd, J = 13.7, 5.7, 2.7 Hz, 1H), 2.32–2.24 (m, 1H), 1.72 (s, 3H); ¹³C {¹H} NMR (100 MHz, CDCl₃): δ 161.9, 158.6, 149.3, 144.5, 141.7, 135.5, 135.4, 130.0, 128.0, 127.9, 126.9, 113.3, 101.0, 90.9, 87.0, 86.4, 85.5, 72.3, 69.9, 63.5, 55.2, 41.4, 4.4; ESI-HRMS: m/z calcd for C₃₃H₃₂ClN₂O₇⁻ [M + Cl] ⁻; 603.1904. found; 603.1913.

Compound (Rp)-3a (Rp-dU)

5'-O-(4,4'-Dimethoxytrityl)-2'-deoxyuridine (**1a**, 1.06 g, 2.0 mmol) was dried by repeated coevaporation with pyridine and toluene and then dissolved in THF (9 mL). TEA (2.78 mL, 20 mmol) was added and the resulting solution was stirred and cooled to -78 °C. Afterwards, a solution of (4*S*,5*R*)-2-chloro-3-phenyl-1,3,2-oxazaphospholidine ((4*S*,5*R*)-2) (0.5 M) in toluene (8.0 mL) was added dropwise at -78 °C. The mixture was warmed to rt and stirred for 1 h. After the reaction completion, the mixture was cooled to -20 °C and diluted with ethyl acetate and washed with a saturated aqueous solution of NaHCO₃ and saturated aqueous solutions of NaCl (twice). The organic layer was then dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by silica gel column chromatography [NH-silica, toluene–ethyl acetate (7:3, v/v), 0.1% TEA] to afford (*R*p)-**3a** (0.66 g, 0.90 mmol, 45%) as colorless foam. ¹H NMR (400 MHz, CHCl₃): δ 7.82 (d, *J* = 8.0 Hz, 1H), 7.38–7.22 (m, 14H), 6.80 (dd, J = 9.0, 3.2 Hz, 4H), 6.33 (t, *J* = 6.2 Hz, 1H), 5.74 (d, *J* = 6.4 Hz, 1H), 5.30 (d, *J* = 8.4 Hz, 1H), 4.97–4.91 (m, 1H), 4.10 (dd, *J* = 6.8, 2.8 Hz, 1H), 3.90–3.86 (m, 1H), 3.77 (s, 3H), 3.76 (s, 3H), 3.65–3.54 (m, 1H), 3.50-3.42 (m, 2H), 3.23–3.15 (m, 1H), 2.65-2.59 (m, 1H), 2.37-2.30 (m, 1H), 1.69–1.62 (m, 2H), 1.22–1.16 (m, 1H), 0.97–0.90 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 162.9, 158.7, 158.6, 150.0, 144.3, 140.2, 138.1 (d, ³*J*_{PC} = 3.9 Hz), 135.2, 135.2, 130.1, 130.0, 128.3, 128.1, 128.0, 127.5, 127.1, 125.4, 113.2, 102.1, 87.0, 85.4 (d, ³*J*_{PC} = 1.9 Hz), 84.9, 82.2 (d, ²*J*_{PC} = 9.6 Hz), 72.3 (d, ²*J*_{PC} = 14.5 Hz), 67.4 (d, ²*J*_{PC} = 2.9 Hz), 62.2, 55.2, 47.2 (d, ²*J*_{PC} = 34.7 Hz), 40.4 (d, ³*J*_{PC} = 4.8 Hz), 28.1, 26.0 (d, ³*J*_{PC} = 3.9 Hz) ³¹P {¹H} NMR (161 MHz, CDCl₃): δ 157.2; FAB-HRMS: m/z calcd for C₄₁H₄₃N₃O₈P⁺ [M + H]⁺ 736.2782. found; 736.2791.

Compound (Sp)-3a (Sp-dU)

5'-O-(4,4'-Dimethoxytrityl)-2'-deoxyuridine (**1a**, 1.06 g, 2.0 mmol) was dried by repeated coevaporation with pyridine and toluene, and THF, and then dissolved in THF (10 mL). TEA (1.98 mL, 14 mmol) was added and the resulting solution was stirred and cooled to -78 °C. Afterwards, a solution of (4*S*,5*R*)-2-chloro-3-phenyl-1,3,2-oxazaphospholidine ((4*S*,5*R*)-2) (0.5 M) in THF (12 mL) was added dropwise at -78 °C. The mixture was warmed to rt and stirred for 2.5 h. The mixture was cooled to -78 °C and a solution of (4*S*,5*R*)-2-chloro-3-phenyl-1,3,2-oxazaphospholidine ((4*S*,5*R*)-2) (0.5 M) in THF (1 mL) was further added to the mixture. The mixture was warmed to rt and stirred for 1 h. After the reaction completion, the mixture was diluted with chloroform (400 mL) and washed with a saturated aqueous solution of NaHCO₃ (150 mL). The water layer was extracted with chloroform (30 mL × 2) and the combined organic layers were then dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by silica gel column chromatography [NH-silica, toluene–ethyl acetate (7:3, v/v), 0.1% TEA] to afford (**Sp**)-**3a** (0.84 g, 1.14 mmol, 57%) as colorless foam.

¹H NMR (400 MHz, CHCl₃): δ 8.40–8.15 (br, 1H) 7.87 (d, J = 8.0 Hz, 1H), 7.41–7.20 (m, 14H), 6.84 (d, J = 8.8 Hz, 4H), 6.31 (t, J = 6.2 Hz, 1H), 5.73 (d, J = 6.4 Hz, 1H), 5.33 (d, J = 7.6 Hz, 1H), 4.97-4.91 (m, 1H), 4.15 (dd, J = 6.4, 2.4 Hz, 1H), 3.95–3.85 (m, 1H), 3.79 (s, 6H), 3.61–3.44 (m, 3H), 3.23–3.13 (m, 1H), 2.53–2.46 (m, 1H), 2.36–2.29 (m, 1H), 1.67–1.60 (m, 2H), 1.26–1.17 (m, 1H), 1.03–0.93 (m, 1H); ¹³C {¹H} NMR (100 MHz, CDCl₃): δ 163.2, 158.6, 158.6, 150.1, 144.2, 140.1, 137.9 (d, ³ J_{PC} = 3.9 Hz), 135.2, 135.1, 130.1, 128.2, 128.1, 128.0, 127.6, 127.1, 126.0, 125.5, 113.2, 102.1, 87.0, 85.1 (d, ³ J_{PC} = 5.9 Hz), 84.7, 82.2 (d, ² J_{PC} = 9.6 Hz), 71.6 (d, ² J_{PC} = 13.5 Hz), 67.4 (d, ² J_{PC} = 2.9 Hz), 62.1, 55.2, 47.2 (d, ² J_{PC} = 34.7 Hz), 40.5, 28.0, 25.9 (d, ³ J_{PC} = 3.9 Hz; ³¹P {¹H} NMR (161 MHz, CDCl₃) δ 156.9; FAB-HRMS: m/z calcd for C₄₁H₄₃N₃O₈P⁺ [M + H]⁺; 736.2782. found; 736.2785.

Compound (Rp)-3c (Rp-d^{Br}U)

5'-O-(4,4'-Dimethoxytrityl)-5-bromo-2'-deoxyuridine (1c, 0.61 g, 1.0 mmol) was dried by repeated co-evaporation with pyridine and toluene, and then dissolved in THF (5.0 mL). TEA (0.97

mL, 7.0 mmol) was added and the solution was stirred and cooled to -78 °C. a solution of (4S,5R)-2chloro-3-phenyl-1,3,2-oxazaphospholidine ((4S,5R)-2) (0.5 M) in THF (6.0 mL) was then added dropwise at -78 °C. The mixture was warmed to rt and stirred for 4 h. After the reaction completion, the mixture was diluted with chloroform (300 mL) and washed with a saturated aqueous solution of NaHCO₃ (100 mL × 3). The water layers were combined and extracted with chloroform (30 mL × 3) and the combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by silica gel column chromatography [NH-silica, toluene–ethyl acetate (8:2 to 0:10, v/v), 0.1% TEA] to afford (*R***p)-3c** (0.33 g, 0.41 mmol, 41%) as colorless foam.

¹H NMR (400 MHz, CHCl₃): δ 8.06 (s, 1H), 7.21–7.43 (m, 14H), 6.81 (d, *J* = 9.2 Hz, 4H), 6.35 (dd, *J* = 7.8, 6.0 Hz, 1H), 5.73 (d, *J* = 6.4 Hz, 1H), 4.93–4.50 (m, br, 2H), 4.16–4.15 (dd, *J* = 5.2, 2.8 Hz 1H), 3.88–3.80 (m, 1H), 3.77 (s×2, 6H), 3.59–3.53 (m, 1H), 3.43–3.35 (m, 2H), 3.22–3.10 (m, 1H), 2.68–2.62 (m, 1H), 2.37–2.30 (m, 1H), 1.68–1.61 (m, 2H), 1.21–1.14 (m, 1H), 0.99–0.89 (m, 1H); ¹³C {¹H} NMR (100 MHz, CDCl₃): δ 159.7, 158.6, 149.9, 144.3, 139.2, 138.0 (d, ³*J*_{PC} = 3.9 Hz), 135.4, 135.3, 130.0, 128.2, 128.0, 127.5, 127.0, 125.7, 125.4, 113.3, 97.2, 87.1, 85.9 (d, ³*J*_{PC} = 1.9 Hz), 85.5, 82.3 (d, ²*J*_{PC} = 9.6 Hz), 73.3 (d, ²*J*_{PC} = 13.5 Hz), 67.4 (d, ²*J*_{PC} = 2.9 Hz), 62.9, 55.2, 47.2 (d, ²*J*_{PC} = 34.7 Hz), 40.6 (d, ³*J*_{PC} = 4.8 Hz), 28.1, 26.0 (d, ³*J*_{PC} = 3.9 Hz); ³¹P {¹H} NMR (161 MHz, CDCl₃): δ 156.5; FAB-HRMS: m/z calcd for C₄₁H₄₁BrN₃NaO₈P⁺ [M + Na]⁺; 836.1707. found; 836.1715.

Compound (Sp)-3c ($Sp-d^{Br}U$)

Compound (*Sp*)-3c was synthesized following the same procedure for (*Rp*)-3c using 1c (0.61 g, 1.0 mmol) and (4*R*,5*S*)-2 (3.0 mmol). The reaction was performed at rt for 2 h. The crude product was purified with silica gel column chromatography [NH-silica, toluene–ethyl acetate (8:2 to 0:10, v/v), 0.5% TEA] to afford (*Sp*)-3c (0.40 g, 0.49 mmol, 49%) as colorless foam.

¹H NMR (400 MHz, CHCl₃): δ 8.12 (s, 1H), 7.44-7.23 (m, 14H), 6.85 (dd, J = 9.2, 1.2 Hz, 4H), 6.31 (dd, J = 7.2, 6.0 Hz, 1H), 5.71 (d, J = 6.4 Hz, 1H), 4.93–4.89 (m, 1H), 4.21 (d, J = 2.8, 1H), 3.92–3.85 (m, 1H), 3.79 (s, 6H), 3.61–3.38 (m, 3H), 3.22–3.10 (m, 1H), 2.56–2.50 (m, 1H), 2.37–2.30 (m, 1H), 1.66–1.59 (m, 2H), 1.26–1.18 (m, 1H), 1.03–0.94 (m, 1H); ¹³C {¹H} NMR (100 MHz, CDCl₃): δ 159.2, 158.7, 149.6, 144.3, 139.2, 137.9 (d, $^{3}J_{PC} = 3.9$ Hz), 135.4, 135.3, 130.1, 130.1, 128.3, 128.1, 128.0, 127.6, 127.1, 125.5, 113.3, 97.1, 87.1, 85.8 (d, $^{3}J_{PC} = 5.8$ Hz), 85.5, 82.4 (d, $^{2}J_{PC} = 9.6$ Hz), 72.7 (d, $^{2}J_{PC} = 12.5$ Hz), 67.4 (d, $^{2}J_{PC} = 2.9$ Hz), 62.8, 55.2, 47.2 (d, $^{2}J_{PC} = 34.7$ Hz), 40.7, 28.1, 26.0 (d, $^{3}J_{PC} = 2.9$ Hz); ³¹P {¹H} NMR (161 MHz, CDCl₃): δ 156.1; FAB-HRMS: m/z calcd for C₄₁H₄₂BrN₃O₈P⁺ [M + H]⁺; 814.1887. found; 814.1887.

Compound (\mathbf{Rp}) -3d $(\mathbf{Rp}$ -d^IU)

Compound (**Rp**)-3d was synthesized following the same procedure for (**Rp**)-3c using 5'-O-(4,4'-Dimethoxytrityl)-5-iodo-2'-deoxyuridine (1d) (0.66 g, 1.0 mmol) and (4*S*,5*R*)-2 (3.0 mmol). The reaction was performed at rt for 1.5 h. The crude product was purified by silica gel column chromatography [NH-silica, toluene–ethyl acetate–acetone (80:20:0 to 0:100:0 to 0:95:5, v/v/v), 0.5% TEA] to afford (*R***p**)-3d (0.36 g, 0.42 mmol, 42%) as colorless foam.

¹H NMR (400 MHz, CHCl₃): δ 8.13 (s, 1H), 7.43–7.21 (m, 14H), 6.82 (d, J = 8.8 Hz, 4H), 6.34 (dd, J = 7.8, 5.2, Hz, 1H), 5.72 (d, J = 6.0 Hz, 1H), 4.92–4.87 (m, 1H), 4.17–4.14 (m, 1H), 3.86–3.76 (m, 7H), 3.63–3.53 (m, 1H), 3.42–3.35 (m, 2H), 3.22–3.13 (m, 1H), 2.67–2.62 (m, 1H), 2.36–2.29 (m, 1H), 1.67–1.60 (m, 2H), 1.21–1.14 (m, 1H), 0.99–0.89 (m, 1H); ¹³C {¹H} NMR (100 MHz, CDCl₃): δ 159.9, 158.7, 149.7, 144.3, 138.1 (d, $^{3}J_{PC} = 3.9$ Hz), 135.4, 135.4, 130.1, 128.3, 128.1, 127.6, 127.1, 125.7, 125.4, 113.3, 87.0, 85.9, 85.5, 82.4 (d, $^{2}J_{PC} = 10.6$ Hz), 73.4 (d, $^{2}J_{PC} = 13.5$ Hz), 68.4, 67.4 (d, $^{2}J_{PC} = 3.9$ Hz), 62.9, 55.2, 47.2 (d, $^{2}J_{PC} = 34.7$ Hz), 40.6 (d, $^{3}J_{PC} = 3.9$ Hz), 28.1, 26.0 (d, $^{3}J_{PC} = 2.9$ Hz); ³¹P {¹H} NMR (161 MHz, CDCl₃) δ 156.2; FAB-HRMS: m/z calcd for C₄₁H₄₂IN₃O₈P⁺ [M + H]⁺; 862.1749. found; 862.1750.

Compound (Sp)-3d (Sp-d^IU)

5'-O-(4,4'-Dimethoxytrityl)-5-iodo-2'-deoxyuridine (1d, 1.32 g, 2.0 mmol) was dried by repeated co-evaporation with pyridine and toluene, and then dissolved in THF (10 mL). TEA (1.95 mL, 14 mmol) was added and the solution was stirred and cooled to -75 °C. A 0.5 M of (4*R*,5*S*)-2-chloro-3-phenyl-1,3,2-oxazaphospholidine ((4*R*,5*S*)-2) in THF (12 mL) was then added dropwise at -75 °C. The mixture was warmed to rt and stirred for 3.5 h. After the reaction completion, the mixture was diluted with chloroform (400 mL) and washed with a saturated aqueous NaHCO₃ solution (150 mL × 3). The water layers were combined and extracted with chloroform (30 mL × 2) and the resulting organic layer was dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by silica gel column chromatography [NH-silica, toluene–ethyl acetate (7:3, v/v), 0.1% TEA to ethyl acetate, 0.5% triethylamine] to afford (*Sp*)-3d (0.86 g, 1.0 mmol, 50%) as colorless foam.

¹H NMR (400 MHz, CHCl₃): δ 8.18 (s, 1H), 7.45–7.25 (m, 14H), 6.86 (d, J = 8.8 Hz, 4H), 6.31 (dd, J = 8.4, 6.0 Hz, 1H), 5.69 (d, J = 6.4 Hz, 1H), 4.91–4.87 (m, 1H), 4.21 (d, J = 2.8 Hz, 1H), 3.90–3.85 (m, 1H), 3.79 (s, 6H), 3.60–3.45 (m, 2H), 3.40–3.36 (m, 1H), 3.21–3.08 (m, 1H), 2.55–2.49 (m, 1H), 2.35–2.29 (m, 1H), 1.66–1.56 (m, 2H), 1.26–1.19 (m, 1H), 1.01–0.94 (m, 1H); ¹³C {¹H} NMR (100 MHz, CDCl₃): δ 159.9, 158.7, 149.7, 144.3, 144.2, 137.9 (d, $^{3}J_{PC} = 3.9$ Hz), 135.3, 135.3, 130.1, 128.3, 128.1, 127.6, 127.1, 125.5, 113.4, 113.3, 87.0, 85.8 (d, $^{3}J_{PC} = 5.8$ Hz), 85.4, 82.4 (d, $^{2}J_{PC} = 8.7$ Hz), 72.8 (d, $^{2}J_{PC} = 13.5$ Hz), 68.4, 67.4 (d, $^{2}J_{PC} = 2.9$ Hz), 62.8, 55.2, 47.2 (d, $^{2}J_{PC} = 34.7$ Hz), 40.7, 28.0, 26.0 (d, $^{3}J_{PC} = 3.9$ Hz); ³¹P {¹H} NMR (161 MHz, CDCl₃): δ 155.9; FAB-HRMS: m/z calcd for C₄₁H₄₂IN₃O₈P⁺ [M + H]⁺; 862.1749. found; 862.1755.

Compound (*R***p**)-3e (*R***p**-d^{pr}U)

5'-O-(4,4'-Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine (1e, 0.53g, 0.93 mmol) was dried with repeated co-evaporation with pyridine and toluene, and then dissolved in THF (5 mL). TEA (0.97 mL, 7.0 mmol) was added and the solution was stirred and cooled to -78 °C. A solution of (4*S*,5*R*)-2- chloro-3-phenyl-1,3,2-oxazaphospholidine ((4*S*,5*R*)-2) (0.5 M) in THF (6.0 mL) was added dropwise

at -78 °C. The mixture was then warmed to rt and stirred for 2.5 h. Afterwards, the mixture was cooled to -78 °C and a solution of (4*S*,5*R*)-2-chloro-3-phenyl-1,3,2-oxazaphospholidine ((4*S*,5*R*)-**2**) (0.5 M) in THF (1.0 mL) was added dropwise to the mixture. The mixture was then warmed again to rt and stirred for 30 min. After the reaction completion, the mixture was diluted with chloroform (300 mL) and washed with a saturated aqueous solution of NaHCO₃ (× 3). The water layers were combined and extracted with chloroform (× 3) and the obtained organic layer was dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by silica gel column chromatography [NH-silica, toluene–ethyl acetate (8:2 to 0:10, v/v), 0.1% TEA] to afford (*R***p**)-3e (0.29 g, 0.40 mmol, 42%) as colorless foam.

¹H NMR (400 MHz, CHCl₃): δ 7.99 (s, 1H), 7.45–7.18 (m, 14H), 6.81 (d, *J* = 8.8 Hz, 4H), 6.31 (dd, *J* = 7.6, 5.2 Hz, 1H), 5.73 (d, *J* = 6.4 Hz, 1H), 4.92–4.87 (m, 1H), 4.15 (dd, *J* = 5.2, 2.8 Hz, 1H), 3.89–3.82 (m, 1H), 3.77 (s × 2, 6H), 3.65–3.50 (m, 1H), 3.41–3.34 (m, 2H), 3.23–3.16 (m, 1H), 2.67–2.62 (m, 1H), 2.37–2.30 (m, 1H), 1.71–1.61 (m, 5H), 1.26–1.14 (m, 1H), 0.99–0.92 (m, 1H); ¹³C {¹H} NMR (100 MHz, CDCl₃): δ 162.1, 158.5, 149.2, 144.5, 141.7, 138.1 (d, ³*J*_{PC} = 3.9 Hz), 135.5, 135.5, 130.0, 128.2, 128.2, 127.9, 127.9, 127.5, 126.9, 125.4, 113.2, 100.9, 90.7, 87.0, 85.8, 85.4, 82.3 (d, ²*J*_{PC} = 9.6 Hz), 73.2 (d, ²*J*_{PC} = 13.5 Hz), 70.0, 67.4 (d, ²*J*_{PC} = 2.9 Hz), 62.9, 55.2, 47.2 (d, ²*J*_{PC} = 34.7 Hz), 40.6 (d, ³*J*_{PC} = 4.8 Hz), 28.1, 26.0 (d, ³*J*_{PC} = 3.9 Hz), 4.4; ³¹P {¹H} NMR (161 MHz, CDCl₃): δ 156.7; FAB-HRMS: m/z calcd for C₄₄H₄₅N₃O₈P⁺ [M + H]⁺; 774.2939. found; 774.2947.

Compound (Sp)-3e (Sp-d^{pr}U)

5'-O-(4,4'-Dimethoxytrityl)-5-propynyl-2'-deoxyuridine (1e) (0.51 g, 0.90 mmol) was dried by repeated co-evaporation with pyridine and toluene, and then dissolved in THF (5.0 mL). TEA (0.97 mL, 7.0 mmol) was added and the solution was stirred and cooled to -78 °C. Afterwards, a 0.5 M solution of (4*R*,5*S*)-2-chloro-3-phenyl-1,3,2-oxazaphospholidine ((4*R*,5*S*)-2) in THF (6.0 mL) was added dropwise at -78 °C. The mixture was warmed to rt and stirred for 3.5 h. After the reaction completion, chloroform was added (300 mL) and the organic layer was washed with a saturated aqueous NaHCO₃ solution (100 mL × 3). The water layers were then combined and extracted with chloroform (30 mL × 3). The obtained organic layers were dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by silica gel column chromatography [NH-silica, toluene–ethyl acetate (8:2 to 0:10, v/v), 0.1% TEA] to afford (*S*p)-3e (0.35 g, 0.47 mmol, 53%) as colorless foam.

¹H NMR (400 MHz, CHCl₃): δ 8.04 (s, 1H), 7.47–7.22 (m, 14H), 6.85 (d, *J* = 8.4 Hz, 4H), 6.30 (dd, *J* = 7.2, 6.0 Hz, 1H), 5.71 (d, *J* = 6.4 Hz, 1H), 4.92–4.88 (m, 1H), 4.10 (d, *J* = 2.8 Hz, 1H), 3.94–3.87 (m, 1H), 3.79 (s, 6H), 3.61–3.51 (m, 1H), 3.45–3.37 (m, 2H), 3.22–3.14 (m, 1H), 2.55–2.50 (m, 1H), 2.37–2.30 (m, 1H), 1.69–1.59 (m, 5H), 1.26–1.18 (m, 1H), 1.03–0.94 (m, 1H); ¹³C {¹H} NMR (100 MHz, CHCl₃): δ 161.6, 158.6, 148.9, 144.5, 141.7, 137.9 (d, ³*J*_{PC} = 3.9 Hz), 135.5, 135.4, 130.0, 128.3, 128.0, 127.9, 127.6, 126.9, 125.5, 113.3, 100.9, 90.9, 87.0, 85.8 (d, ³*J*_{PC} = 4.8 Hz), 85.3, 82.3 (²*J*_{PC} = 9.6 Hz), 72.7 (d, ²*J*_{PC} =12.5 Hz), 69.9, 67.4 (d, ²*J*_{PC} = 2.9 Hz), 62.9, 55.2, 47.2 (d, ²*J*_{PC} = 34.7 Hz),

40.7, 28.1, 26.0 (d, ${}^{3}J_{PC}$ = 2.9 Hz), 4.4; ${}^{31}P$ { ${}^{1}H$ } NMR (161 MHz, CDCl₃): δ 156.1; FAB-HRMS: m/z calcd for C₄₄H₄₅N₃O₈P⁺ [M+H]⁺; 774.2939. found; 774.2946.



Figure S2. ¹H NMR spectra of compound 1e



Figure S3. ¹³C NMR spectra of compound 1e



Figure S5. ¹³C NMR spectra of compound (*R*p)-3a



Figure S6. ³¹P NMR spectra of compound (*R*p)-3a



Figure S7. ¹H NMR spectra of compound (Sp)-3a



Figure S8. ¹³C NMR spectra of compound (Sp)-3a



Figure S9. ³¹P NMR spectra of compound (Sp)-3a



Figure S10. ¹H NMR spectra of compound (*R*p)-3c



Figure S11. ¹³C NMR spectra of compound (*R*p)-3c



Figure S12. ³¹P NMR spectra of compound (*R*p)-3c



Figure S13. ¹H NMR spectra of compound (Sp)-3c



Figure S14. ¹³C NMR spectra of compound (Sp)-3c



Figure S15. ³¹P NMR spectra of compound (Sp)-3c







Figure S17. ¹³C NMR spectra of compound (*R*p)-3d



Figure S18. ³¹P NMR spectra of compound (*R*p)-3d



Figure S19. ¹H NMR spectra of compound (Sp)-3d



Figure S20. ¹³C NMR spectra of compound (Sp)-3d



Figure S21. ³¹P NMR spectra of compound (Sp)-3d



Figure S22. ¹H NMR spectra of compound (*R*p)-3e



Figure S23. ¹³C NMR spectra of compound (*R*p)-3e



Figure S24. ³¹P NMR spectra of compound (*R*p)-3e



Figure S25. ¹H NMR spectra of compound (Sp)-3e



Figure S26. ¹³C NMR spectra of compound (Sp)-3e



Figure S27. ³¹P NMR spectra of compound (Sp)-3e



Figure S28. RP-HPLC profile of purified (*R*p)-4a ((*R*p)-dCG(U_{PS})₈CG). RP-HPLC analysis (UV detection at 260 nm) was performed with a linear gradient of 0-30% CH₃CN in 0.1 M TEAA buffer (pH 7.0) at 30 °C for 60 min with a flow rate of 0.5 mL/min.



Figure S29. RP-HPLC profile of purified **(Sp)-4a** ((Sp)-dCG(U_{PS})₈CG). RP-HPLC analysis (UV detection at 260 nm) was performed with a linear gradient of 0-30% CH₃CN in 0.1 M TEAA buffer (pH 7.0) at 30 °C for 60 min with a flow rate of 0.5 mL/min.



Figure S30. RP-HPLC profile of purified (*R*p)-4b ((*R*p)-dCG(T_{PS})₈CG). RP-HPLC analysis (UV detection at 260 nm) was performed with a linear gradient of 0–30% CH₃CN in 0.1 M TEAA buffer (pH 7.0) at 30 °C for 60 min with a flow rate of 0.5 mL/min.



Figure S31. RP-HPLC profile of purified (*Sp*)-4b (all-(*Sp*)-PS-dCG(T_{PS})₈CG). RP-HPLC analysis (UV detection at 260 nm) was performed with a linear gradient of 0–30% CH₃CN in 0.1 M TEAA buffer (pH 7.0) at 30 °C for 60 min with a flow rate of 0.5 mL/min.



Figure S32. RP-HPLC profile of purified (*R*p)-4c ((*R*p)-dCG($^{Br}U_{PS}$) $_{8}$ CG). RP-HPLC analysis (UV detection at 260 nm) was performed with a linear gradient of 0–30% CH₃CN in 0.1 M TEAA buffer (pH 7.0) at 30 °C for 60 min with a flow rate of 0.5 mL/min.



Figure S33. RP-HPLC profile of purified (*Sp*)-4c ((*Sp*)-dCG($^{Br}U_{PS}$)₈CG). RP-HPLC analysis (UV detection at 260 nm) was performed with a linear gradient of 0–30% CH₃CN in 0.1 M TEAA buffer (pH 7.0) at 30 °C for 60 min with a flow rate of 0.5 mL/min.



Figure S34. RP-HPLC profile of purified (*R*p)-4d ((*R*p)-dCG($^{I}U_{PS}$)₈CG). RP-HPLC analysis (UV detection at 260 nm) was performed with a linear gradient of 0–30% CH₃CN in 0.1 M TEAA buffer (pH 7.0) at 30 °C for 60 min with a flow rate of 0.5 mL/min.



Figure S35. RP-HPLC profile of purified (*Sp*)-4d ((*Sp*)-dCG($^{1}U_{PS}$)₈CG). RP-HPLC analysis (UV detection at 260 nm) was performed with a linear gradient of 0–30% CH₃CN in 0.1 M TEAA buffer (pH 7.0) at 30 °C for 60 min with a flow rate of 0.5 mL/min.



Figure S36. RP-HPLC profile of purified (*R***p**)-4e ((*R***p**)-dCG($^{\text{pr}}$ U_{PS})₈CG). RP-HPLC analysis (UV detection at 260 nm) was performed with a linear gradient of 0–30% CH₃CN in 0.1 M TEAA buffer (pH 7.0) at 30 °C for 60 min with a flow rate of 0.5 mL/min.



Figure S37. RP-HPLC profile of purified (*Sp*)-4e ((*Sp*)-dCG($^{pr}U_{PS}$)₈CG). RP-HPLC analysis (UV detection at 260 nm) was performed with a linear gradient of 0–30% CH₃CN in 0.1 M TEAA buffer (pH 7.0) at 30 °C for 60 min with a flow rate of 0.5 mL/min.



FigureS38.3-DviewofanDNA/DNAduplex,dCGCGTAGCATGCGC/dGCGCATGCCATGCG(ATGCGCG(PDB)2M2C, NMR solution structure).The underlined T (PoT) residues are displayed in ball and stick style. The distances betweenthe carbon atom of the methyl group of each thymine and a pro-Rp oxygen atom in aphophodiester linkage were 4.7, 5.6, and 5.8 Å, respectively.



Figure S39. RP-HPLC profiles of the mixture of PO- or PO/PS chimeric-DNAs and their complementary RNA (rCGA₈CG) after treatment with 20U/100 μ L RNase H at 20 °C for 30 min: (a) PO-dCGT₈CG (b) (*R*p)-dCG(T_{PS})₈CG (*R*p-(4b)) (c) (*S*p)-dCG(T_{PS})₈CG (*S*p-(4b)) (d) PO-dCG(^{pr}U)₈CG (e) (*R*p)-dCG(^{pr}U_{PS})₈CG (*R*p-(4e)) (f) (*S*p)-dCG(^{pr}U_{PS})₈CG (*S*p-(4e)). RP-HPLC analyses (UV detection at 260 nm) were performed with a linear gradient of 0–30% CH₃CN in 0.1 M TEAA buffer (pH 7.0) at 20 °C for 60 min with a flow rate of 0.5 mL/min.